	US 12,202,902 B2
	FLT3-specific chimeric antigen receptors and methods using same
Christopher D. Chien, Falls Church, VA (US); and Terry J. Fry, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Mar. 8, 2022, as Appl. No. 17/689,698.
Application 17/689,698 is a continuation of application No. 16/304,552, granted, now 11,299,546, previously published as PCT/US2017/034691, filed on May 26, 2017.
Claims priority of provisional application 62/342,394, filed on May 27, 2016.
Prior Publication US 2022/0259317 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 38/00 (2013.01); A61K 39/395 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464411 (2023.05); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2815 (2013.01); G01N 33/57426 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2300/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2319/03 (2013.01); G01N 2333/715 (2013.01)]

19 Claims

1. An isolated NK cell comprising a chimeric antigen receptor (CAR),

wherein the CAR comprises an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain,

wherein the antigen binding domain comprises a single chain variable fragment (scFv) comprising from N-terminus to C-terminus (a) the heavy chain variable region CDR1, CDR2, and CDR3 sequences of SEQ ID NOS: 6, 8, and 10 and (b) the light chain variable region CDR1, CDR2, and CDR3 sequences of SEQ ID NOS: 14, 16, and 18.